Navigation Links
Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
Date:8/6/2009

CARLSBAD, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its financial results for the quarter ended June 30, 2009. During 2009 Isis has continued to successfully execute its business strategy and as a result reported $669,000 of pro forma net income for the quarter ended June 30, 2009, a significant improvement over the same period in 2008. Isis also reported a pro forma net operating loss of $1.3 million for the second quarter compared to pro forma net operating income of $4.6 million for the same period in 2008. Maintaining its strong cash position, Isis ended the quarter with $637.5 million of cash and remains on track to end 2009 with more than $550 million of cash. Isis also remains on track to meet its guidance of more than $145 million of pro forma net income and a pro forma net operating loss in the low to mid $20 million range, in both cases excluding non-cash stock compensation expense.

"Our strong financial performance is a direct result of the success of our technology platform and business strategy. We and our partners are advancing our large and growing pipeline of 19 drugs in development. Our partnership strategy not only allows our drugs to move forward effectively toward the market but also provides us with significant short and intermediate term financial benefits that enable us to continue to advance the technology and fill the pipeline with more exciting new drugs," said B. Lynne Parshall, COO and CFO of Isis.

Upcoming Key Milestones

  • Report full data from a Phase 3 study evaluating mipomersen in homozygous Familial Hypercholesterolemia (FH) patients; positive top line data was reported in May 2009
  • Report data from additional mipomersen studies in othe
    '/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Spherix Reports Second Quarter Earnings
3. Tapestry Reports Second Quarter 2007 Results
4. Callisto Reports on Second-Quarter 2007 Milestones
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Biopure Reports on Meeting with the FDA
10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP ... 225mg and 300mg oral tablets, indicated for use in ... for Propafenone Hydrochloride 150mg, 225mg and 300mg tablets was ... Arthur S. Przybyl , President and Chief Executive ... of our fourth product from the portfolio of approved ...
(Date:3/31/2015)... -- Biorasi , a full-service CRO powered ... Medidata , the leading global provider of ... Offering therapeutic expertise in a number of areas, ... capture (EDC), management and reporting system, Medidata Rave®, ... clinical trial business. ...
(Date:3/31/2015)... 31, 2015  Cindy Dellecker, former Senior Vice President of ... has accepted a position on the TruHearing Advisory Board. ... care to TruHearing and will act as an advisor ... "Hearing healthcare has always been an important ... personal level," said Dellecker.  "I,m excited to be on ...
Breaking Medicine Technology:ANI Pharmaceuticals Announces the Launch of Propafenone Tablets 2ANI Pharmaceuticals Announces the Launch of Propafenone Tablets 3Biorasi Selects Medidata's Cloud-Based Platform for Optimal Trial Operations 2Biorasi Selects Medidata's Cloud-Based Platform for Optimal Trial Operations 3Biorasi Selects Medidata's Cloud-Based Platform for Optimal Trial Operations 4TruHearing Announces Addition of Cindy Dellecker to Advisory Board 2
... YORK, March 9 /PRNewswire-Asia-FirstCall/ -- American Oriental,Bioengineering, ... China-based pharmaceutical company,dedicated to improving health through ... range of prescription and over the counter ... initiating a phase one clinical,trial of AOBO-001, ...
... Association (AMA) Foundation announced today the 28 recipients of the 2009 Seed ... to medical students, physician residents and fellows to conduct basic science, applied ... in the following four categories: , , ... HIV/AIDS , ...
Cached Medicine Technology:American Oriental Bioengineering to Initiate a Phase One Clinical Trial in the United States of AOBO-001 Oral Capsule 2American Oriental Bioengineering to Initiate a Phase One Clinical Trial in the United States of AOBO-001 Oral Capsule 3AMA Foundation Announces Seed Grant Research Recipients 2AMA Foundation Announces Seed Grant Research Recipients 3
(Date:3/31/2015)... Illinois (PRWEB) March 31, 2015 ... Visio Stencils Device Library for documenting and diagramming ... following Visio Stencils: , Manufacturer / Device ... PowerEdge r720, Dell PowerEdge r520, Dell PowerEdge r630, ... Power 8 Series, EMC VMAX 100K, VMAX 200K, ...
(Date:3/31/2015)... Indiana (PRWEB) March 31, 2015 ... DeRose in Youngstown, Ohio in 1987. This ... the curve with not just customer satisfaction, but ... been added to the well-stocked arsenal of Yesco ... by American Green Technology® (AGT). The patented environmental ...
(Date:3/31/2015)... 31, 2015 Burns Engineering announces 3-Day Quick ... for the Food & Beverage, Pharmaceutical and Biotech markets. These ... ASME-BPE compliant and are now available as part of Burns’ ... , The S01 and S03 with 1/8” and ... process connections used in process lines 1/4” and larger. ...
(Date:3/31/2015)... 31, 2015 The Heart Fit ... Calgary and surrounding areas. External Counterpulsation is an ... artery disease, specifically stable coronary artery disease. ... is used extensively all over the world for ... Calgarians (Albertans) are extremely fortunate to have the ...
(Date:3/31/2015)... Orlando, FL (PRWEB) March 31, 2015 ... and Sickness Insurance programs, issues a travel advisory to ... Health care costs in the United States are higher ... than even in developed countries. For example, a ... while the same procedure costs about $34,358 . ...
Breaking Medicine News(10 mins):Health News:Altima Adds More Hardware Devices to its NetZoom™ Visio® Stencils Device Library 2Health News:American Green Technology® Signs Exclusive Agreement to Distribute Health Risk Management System in Midwest 2Health News:Burns Engineering Now Offers 3-Day Quick Ship on Sanitary RTDs and Thermocouples 2Health News:New Heart Disease Treatment Called External Counterpulsation (EECP) helps people of Alberta Who Have Failed or Are Not Suitable For Heart Stents or Surgery 2Health News:India Network Foundation issues travel advisory to all US bound travelers on visitor health insurance requirements 2Health News:India Network Foundation issues travel advisory to all US bound travelers on visitor health insurance requirements 3
... is in the process of doing away with a commonly ... phase out the ‘Aropax’ brand of paroxetine and bring in ... used by about 49,000 New Zealanders. ,This move ... maintains that both drugs are the same, except for the ...
... Forest University Baptist Medical Center are helping to lead ... that will test 3,000 patients in an effort to ... patients. ,Though doctors have promoted the value of ... training has not been definitively established as safe in ...
... why we shed tears. But exactly what our tears are made ... study sheds some light on the complex design of tears. What ... made up of three distinct, microscopic layers. The middle, watery layer ... – is sandwiched between a layer of mucus and an outer ...
... is an alarming rise of gambling and gamblers in Britain. ... gambling and casinos then on vegetables and fruits. ... been spent on gambling in United Kingdom. Online gambling has ... time. ,The British medical Association (BMA) has expressed ...
... The death of a 47-year-old man who had worked for ... hundreds of ex-employees, who had also been exposed to toxic ... Thursday, prompting more than 500 protestors, who said he had ... roads and demand an autopsy to assess the possibility of ...
... Plc, Europe's pharmaceutical giant, is finalizing its plan of action, ... Gardasil, in a bid to establish the most effective vaccine ... conducted in the United States, will seek to evaluate the ... to two strains of the human papillomavirus. This virus is ...
Cached Medicine News:Health News:New International Study to Test Exercise in Heart Failure Patients 2Health News:New International Study to Test Exercise in Heart Failure Patients 3Health News:Tears Reveal Some of Their Deepest Secrets to Researchers 2Health News:Tears Reveal Some of Their Deepest Secrets to Researchers 3Health News:Ex-workers Ask HLL to Accept Liability for Mercury Deaths 2
View Mex-2 is designed for out-patient surgery, hospital rounds and house calls....
It provides excellent illumination from an inexpensive platform and is mounted on the comfortable UltraLite headband....
Headlight module is mounted on UltraLite Plus headband....
... rapid rise in intracranial ... intervention and continuous monitoring. ... technology that gets to ... Its versatility makes it ...
Medicine Products: